Munich, 12 August 2015 - WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) was informed today that Roche is discontinuing its partnership with the WILEX subsidiary Heidelberg Pharma GmbH with respect to their collaboration in the field of antibody-targeted amanitin conjugates (ATACs). The licence agreement was signed in 2013 and expanded in October 2014.
Roche has recently increased the focus of its oncology research strategy on cancer immunotherapies and deprioritised other internal and external oncology research programmes accordingly. Affected by this deprioritisation are the collaborative research efforts with Heidelberg Pharma, which in recent years have progressed well, on schedule, and in a mutually satisfactory manner.
Updated financial outlook for 2015
As a consequence of the termination of existing collaborative efforts to develop and identify novel antibody-targeted amanitin conjugates (ATACs), WILEX AG revised today its financial outlook for the current financial year. Due to lower sales revenues WILEX's cash reach is reduced from the end of the second quarter 2016 to the first quarter of 2016.
About WILEX and Heidelberg Pharma WILEX AG is a biopharmaceutical company which has a ready for partnering portfolio of antibody-based diagnostic and therapeutic Phase III product candidates for the detection and targeted treatment of clear cell renal cell carcinoma. Research and development focus on the operations of its subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances the development of the innovative platform technology for antibody drug conjugates (ADC technology) and provides pre-clinical drug discovery and development services. WILEX is listed at the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at http://www.wilex.com/. Contact IR/PR Support WILEX AG MC Services AG Sylvia Wimmer Katja Arnold (CIRO) Corporate Communications Executive Director Tel.: +49 (0)89-41 31 38-29 Tel.: +49-89-210 228-40 E-mail: investors[at]wilex.com Mobile: +49 160 9360 3022 Grillparzerstr. 18, 81675 Munich E-mail: katja.arnold[at]mc-services.eu </pre> This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as 'estimates', 'believes', 'expects', 'may', 'will', 'should', 'future', 'potential' or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments. 12.08.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: WILEX AG Grillparzerstr. 18 81675 MÃ¼nchen Germany Phone: +49 (0)89 41 31 38 - 0 Fax: +49 (0)89 41 31 38 - 99 E-mail: [email protected] Internet: www.wilex.com ISIN: DE000A11QVV0 WKN: A11QVV Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart End of Announcement DGAP News-Service